Adalta

Filamon, located in Camberwell, Victoria, is dedicated to pioneering innovative, science-driven therapies aimed at addressing chronic inflammatory and degenerative diseases that affect the aging population. With a focus on treating these conditions as interconnected outcomes of widespread inflammation, the company aims to improve the quality of life for individuals grappling with multiple chronic diseases. Utilizing a multimodal approach, Filamon's therapies are designed to target complex gene networks associated with chronic inflammation, moving beyond conventional monomodal treatments. Their breakthrough research encompasses four technology platforms, leading to the development of first-in-class drugs that promise new hope for conditions previously deemed intractable. Generated from the website

Tryptamine Therapeutics, located in Camberwell, Victoria, is a clinical-stage biotechnology company dedicated to pioneering innovative solutions in psychedelic drug development aimed at enhancing patient care. The company focuses on addressing neuropsychiatric disorders through therapeutic dosing of synthetic psilocybin and IV-infused psilocin, which seeks to overcome the limitations associated with orally administered treatments. Driven by a commitment to patient outcomes, Tryptamine Therapeutics is developing proprietary formulations and advanced dosing methods to improve the psychedelic experience for patients suffering from chronic pain and other conditions. With a strong management team and ongoing global patent pursuits, the company is on a mission to transform the treatment landscape for diseases with unmet medical needs. Generated from the website